title: [Is there a rationale in combining anticonvulsants for bipolar patients?].
abstract: High recurrence rates, chronicity and severity as well as high incidence rates of therapy refractory of bipolar disorder, different clinical manifestations of episodes, and psychiatric comorbidities demand combined drug treatment strategies. Polypharmacy is reported in more than 40 % of bipolar in- and out patients. The aim of this paper is to evaluate the incidence of combined mood stabilizer prescriptions and to delineate preclinical and clinical rationales for these treatment options. Over the last decade frequency of combination therapies with 2 or more anticonvulsants increased from 4.5 to more than 12 %. On the background of the dynamic complexity and being aware of potential side effects of such therapy paradigms, the authors provide a rationale for a thoughtful anticonvulsant combination therapy, considering the preclinical findings from epilepsy research, and clinical trials in bipolar disorder.
authors.affiliation: Abteilung der Psychiatrie I, Landeskrankenhaus Rankweil. andreas.conca@lkhr.at
authors.forename: Andreas
authors.initials: A
authors.lastname: Conca
authors.forename: Renate
authors.initials: R
authors.lastname: Grohmann
authors.forename: Jan
authors.initials: J
authors.lastname: Di Pauli
authors.forename: Armand
authors.initials: A
authors.lastname: Hausmann
mesh_terms: D000208:Acute Disease; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D018692:Antimanic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy*; D002908:Chronic Disease; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D018020:Lithium Compounds / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention
chemical_list: D000927:Anticonvulsants; D018692:Antimanic Agents; D018020:Lithium Compounds